Guest editorial: How do we apply genetic testing for breast cancer susceptibility to clinical practice?

K. Hughes,C. Roche

DOI: https://doi.org/10.1002/(SICI)1096-9098(199607)62:3<155::AID-JSO1>3.0.CO;2-6

1996-07-01

Journal of Surgical Oncology

Abstract:

What problem does this paper attempt to address?

A Case of Guillain-Barré Syndrome Associated With COVID-19

Kartikeya Rajdev,Navin Victor,Elaine S Buckholtz,Praveen Hariharan,Muhammad Ahsan Saeed,Daniel M Hershberger,Sabin Bista

DOI: https://doi.org/10.1177/2324709620961198

Abstract:A novel member of human RNA coronavirus, which is an enveloped betacoronavirus, has been termed severe acute respiratory syndrome coronavirus-2 (SARS COV-2). The illness caused by SARS COV-2 is referred to as the coronavirus disease 2019 (COVID-19). It is a highly contagious disease that has resulted in a global pandemic. The clinical spectrum of COVID-19 ranges from asymptomatic illness to acute respiratory distress syndrome, septic shock, multi-organ dysfunction, and death. The most common symptoms include fever, fatigue, dry cough, dyspnea, and diarrhea. Neurological manifestations have also been reported. However, the data on the association of Guillain-Barré syndrome (GBS) with COVID-19 are scarce. We report a rare case of a COVID-19-positive 36-year-old immunocompromised male who presented with clinical features of GBS. His clinical examination showed generalized weakness and hyporeflexia. The cerebrospinal fluid (CSF) analysis showed albuminocytological dissociation. Intravenous immunoglobulin (IVIG) was administered based on the high clinical suspicion of GBS. The patient's neurological condition worsened with progression to bulbar weakness and ultimately neuromuscular respiratory failure requiring mechanical ventilation. His nerve conduction studies were consistent with demyelinating polyneuropathy. He received five plasma exchange treatments and was successfully weaned from mechanical ventilation. A brain and cervical spine magnetic resonance imaging was obtained to rule out other causes, which was normal. COVID-19 is believed to cause a dysregulated immune system, which likely plays an important role in the neuropathogenesis of GBS.
COVID-19 AND NEUROLOGICAL AUTOIMMUNITY: A CASE OF SARS-COV-2-INDUCED GUILLAIN-BARRÉ SYNDROME

Artem Minalyan,Vincent Chan,Qian Zhang,Franklin Thelmo

DOI: https://doi.org/10.1016/j.chest.2021.07.908

2021-01-01

CHEST Journal

Abstract:INTRODUCTION:With the ongoing COVID-19 pandemic, a number of rare complications have been reported.We present a case of a rare neurological complication in a patient with a newly diagnosed COVID-19 infection.CASE PRESENTATION: A 64-year-old man with recently treated intraabdominal infection (antibiotics and drainage) presented to the Emergency Department (ED) with a 3-day history of fevers, intermittent right-sided flank pain, and urinary symptoms.He was found to have a complicated urinary tract infection (UTI) due to Klebsiella pneumoniae.He was started on intravenous antibiotics.He was tested positive for the SARS-CoV2 virus.On day 5, he developed progressive hypoxemia with bilateral infiltrates on the chest x-ray.Remdesivir and dexamethasone were initiated.Despite that, the patient developed further progression of respiratory failure requiring intubation.He then failed extubation.On exam, the patient was noted to have profound bilateral lower extremity weakness (motor strength: upper extremities -4/5 bilaterally; lower extremities -2/5), absent deep tendon reflexes.Magnetic resonance imaging (MRI) of the brain and spine did not show any abnormal lesions.Lumbar puncture showed an elevated protein (147 (15-40 mg/dL)) with absent cells in the cerebrospinal fluid (CSF) (albuminocytologic dissociation).He was diagnosed with Guillain-Barré syndrome (GBS).Therapeutic plasma exchange (TPE) was initiated (IVIG was not recommended given the potential risk of hypercoagulability).The patient completed 5 days of TPE.The patient noted some improvement in the strength of upper extremities.Unfortunately, the patient later developed a multiorgan failure with recurrent aspiration events and renal failure.The patient and his family decided to proceed with hospice. DISCUSSION: GBS is a heterogenous acute immune-mediated polyneuropathy commonly triggered by various viral infections.There have been several reports of SARS-CoV-2 infection triggering both primary and recurrent GBS.It is thought to be induced by the cross-reactivity of viral antigens with myelin.The diagnosis of GBS should be suspected in patients with progressive symmetric muscle weakness and absent deep tendon reflexes.Electrodiagnostic (not done in our patient) and CSF studies are usually done to confirm the diagnosis.Albuminocytologic dissociation (elevated protein with normal WBC count in the CSF) can be detected in most patients, especially if CSF is obtained after 7 days since the onset of symptoms.Supportive treatment with close monitoring of respiratory function is extremely important in affected patients.Disease-modifying therapies include the use of IVIG or TPE.CONCLUSIONS: With the myriad of publications related to SARS-CoV-2 infection, we continue to learn more about the culprit virus.We believe that healthcare workers should be aware of autoimmune complications of COVID-19 infection given the ongoing pandemic.
CPR training. Finally, system sellers are laying out real-world steps to computerized patient records.

A. Solovy

1998-04-20

Abstract:
Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Mohammad Aladawi,Mohamed Elfil,Baha Abu-Esheh,Deaa Abu Jazar,Ahmad Armouti,Ahmed Bayoumi,Ezequiel Piccione

DOI: https://doi.org/10.1017/cjn.2021.102

2021-05-05

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Abstract:ABSTRACT: Background: In January 2020, the first case of Guillain Barre syndrome (GBS) due to COVID-19 was documented in China. GBS is known to be postinfectious following several types of infections. Although causality can only be proven through large epidemiological studies, we intended to study this association by a thorough review of the literature. Methods: We searched PubMed, EMBASE, and Google scholar and included all papers with English or Spanish full text and original data of patients with GBS and recent COVID infection. Variables of interest were demographics, diagnostic investigations, and the latency between arboviral and neurological symptoms. Further variables were pooled to identify GBS clinical and electrophysiological variants, used treatments, and outcomes. The certainty of GBS diagnosis was verified using Brighton criteria. Results: We identified a total of 109 GBS cases. Ninety-nine cases had confirmed COVID-19 infection with an average age of 56.07 years. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d. The predominant GBS clinical and electromyography variants were the classical sensorimotor GBS and acute demyelinating polyneuropathy respectively. Forty cases required intensive care, 33 cases required mechanical ventilation, and 6 cases were complicated by death. Conclusions: Studies on COVID-19-related GBS commonly reported sensorimotor demyelinating GBS with frequent facial palsy. The time between the onset of infectious and neurological symptoms suggests a postinfectious mechanism. Early diagnosis of GBS in COVID-19 patients is important as it might be associated with a severe disease course requiring intensive care and mechanical ventilation.
Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication

Uddalak Chakraborty,Arkapravo Hati,Atanu Chandra

DOI: https://doi.org/10.1016/j.dsx.2021.102326

Abstract:Background and aims: The COVID-19 pandemic has turned the world topsy turvy since its emergence and has claimed innumerable lives worldwide. Neurological manifestations of the disease have raised several eyebrows around the world among which Guillain-Barré syndrome (GBS) deserve special mention. Although majority of the cases of the coronavirus disease 2019 (COVID-19) present with respiratory symptoms, extrapulmonary manifestations are being increasingly reported. We conducted this study to analyze detailed clinical presentations and outcome in a series of eight cases (n = 8) with COVID-19 associated GBS. Methods: An observational prospective study was conducted among patients with post-infectious/para-infectious GBS. 8 patients were subclassified into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) as per electrodiagnostic criteria and were followed up from admission to 6 months post discharge, to obtain a comprehensive clinical profile and outcome in these patients. Results: The diagnosis of GBS was confirmed as per Asbury criteria, supported by electrodiagnostic features in nerve conduction velocity test. Among the series of 8 patients, 3 were diagnosed as AIDP, 3 had AMAN and the remaining 2 patients had AMSAN. 3 patients of GBS were afebrile and were diagnosed as COVID-19 after a positive assay on routine screening. Cerebro-spinal fluid analysis for SARS-Cov-2 RT-PCR and serum anti-ganglioside antibodies were negative in all the patients. Conclusion: GBS in patients with COVID-19 should be differentiated from critical illness neuropathy and myopathy. Early diagnosis is important as it is associated with poor outcome and prolonged invasive ventilation.
Bilateral Facial Paralysis in an Atypical Clinical Onset of COVID-Associated Guillain-Barre Syndrome

Ahmad Taftaf,Claudine A Vera Cruz,Haytham Al-Qasmi,Mohammed Al-Qasmi

DOI: https://doi.org/10.7759/cureus.63498

2024-06-30

Cureus

Abstract:Coronavirus disease (COVID-19) has been associated with a diverse range of extrapulmonary manifestations since its global outbreak in 2019. One of its rare complications is Guillain-Barre Syndrome (GBS), a post-infectious neurological disorder that manifests with a characteristic ascending limb paralysis. Here, we describe the atypical case of a 42-year-old African American male who developed bilateral facial paralysis within five weeks of testing positive for COVID-19. Initial diagnostic imaging and blood studies were negative for acute pathology. Albuminocytological dissociation found in a subsequent analysis of the patient's cerebrospinal fluid and his appropriate therapeutic response to intravenous immunoglobulin (IVIg) indicated GBS as the most likely diagnosis.
Case report: Rare Guillain-Barré syndrome variants and mild encephalitis/encephalopathy with a reversible splenial lesion as the para-infectious manifestations of SARS-CoV-2 infection

Wei Si,Yuanrui Li,Ganqin Du

DOI: https://doi.org/10.3389/fimmu.2024.1458231

2024-10-04

Abstract:Background: The Coronavirus disease 19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a threat to human health. Although the COVID-19 pandemic is finished, some peoples are still suffering from this disease. Herein, we report the first case of SARS-CoV-2-associated Guillain-Barré syndrome (GBS) presenting as polyneuritis cranialis (PNC) and acute panautonomic neuropathy (APN) variants, accompanied by mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) and hyponatremia. Case presentation: A 32-year-old female patient with symptoms indicating multiple cranial nerve involvement, as well as sympathetic and parasympathetic nervous system dysfunction, was diagnosed as SARS-CoV-2-associated GBS presenting as PNC and APN variants, accompanied by MERS and hyponatremia. Following treatment with immunoglobulin, methylprednisolone, and symptomatic care, the patient's inflammatory cytokines and serum sodium became normal. However, some residual symptoms such as postural hypotension, fatigue, and mild dysarthria persisted at the 9-month follow-up. Conclusion: This case highlights the unique presentation of SARS-CoV-2 infection. The involvement of both the central nervous system (CNS) and the peripheral nervous system (PNS) in this case underscores the complex neurological manifestations of COVID-19. Although the exact underlying pathogenesis of this case is unclear, inflammatory cytokines, particularly IL-6, may be implicated. Further research is needed to better understand the mechanisms underlying these complications and to optimize treatment strategies for affected patients.
HYGIENIC EVALUATION OF THE FOOD FISHES, TILAPIA MELANOPLEURA AND TILAPIA MOSSAMBICA NURTURED IN SEWAGE EFFLUENT.

C. R. Mackenzie,G. Campbell

Abstract:
Guillain-Barré Syndrome Complicated by Severe Acute Respiratory Distress Syndrome: A Case Report

Yao Sun,Huiying Zhao,Youzhong An

DOI: https://doi.org/10.2147/IMCRJ.S462543

2024-09-27

Abstract:Guillain-Barré syndrome (GBS) stands out as the most prevalent and severe acute immune-mediated paralytic neuropathy. Approximately 30% of patients experience respiratory failure necessitating admission to the intensive care unit (ICU) and invasive mechanical ventilation. The management of diseases concomitant with acute respiratory distress syndrome (ARDS) poses significant challenges. This case report illustrates the swift development of ARDS in a patient with GBS, explores the utility of the biomarker neurofilament light chain, and highlights the unexpected advantages of proactive ARDS intervention.
Bradycardia unresponded to atropin testing was successfully treated with therapeutic plasma exchange in a patient with severe COVID-19 complicated by Guillain-Barré syndrome: A case report

Sy Duong-Quy,Duc Huynh-Truong-Anh,Quynh Tran-Xuan,Tien Nguyen-Quang,Thanh Nguyen-Thi-Kim,Thanh Nguyen-Chi,Thuy Tran-Ngoc-Anh,Nam Nguyen-Van-Hoai,Mai Do-Thi-Thu,Tram Tang-Thi-Thao,Khue Bui-Diem,Tien Hoang-Anh,Thu Nguyen-Ngoc-Phuong,Vinh Nguyen-Nhu

DOI: https://doi.org/10.3389/fcvm.2022.1035896

IF: 3.6

2023-01-20

Frontiers in Cardiovascular Medicine

Abstract:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been an alarming situation worldwide for the past 2 years. The symptoms of coronavirus disease 2019 (COVID-19) are not only confined to the respiratory system but also affect a multitude of organ systems. Bradycardia associated with Guillain-Barré syndrome (GBS) is a rare autonomic and peripheral neurological complication of COVID-19. In this case report, we present the case of a 26-year-old man diagnosed with bradycardia associated with GBS after contracting COVID-19. Initially, this patient had the classical symptoms of COVID-19 and was hospitalized in the intensive care unit (ICU) for acute respiratory distress syndrome (ARDS). Then, he developed weakness in the lower extremities, diminished tendon reflexes, a loss of sensation without sphincter muscle disorders, and bradycardia. His bradycardia did not respond to atropine. The patient was treated concurrently with a high-flow nasal cannula, systemic corticosteroids, anticoagulation, and therapeutic plasma exchange (TPE) for COVID-19-induced ARDS, bradycardia, and GBS. His ARDS and bradycardia improved after the first cycle of TPE and medical treatment. After three cycles of TPE, the patient progressively recovered his muscle strength in the lower limbs and regained peripheral sensation. He was discharged from the hospital in stable condition after 4 weeks of hospitalization and was followed up after 6 months for cardiorespiratory and neurological complications. This case report elucidates the potential difficulties and challenges that physicians may encounter in diagnosing and treating COVID-19-induced bradycardia and GBS during the pandemic outbreak. However, the patient outcomes with the treatment combining the conventional treatment with therapeutic plasma exchange seem to be optimistic.

cardiac & cardiovascular systems
A Case of Intractable Hypophosphatemia in a Patient with Guillain-Barré Syndrome and Encephalitis after SARS-CoV-2 Infection

Yawen Zheng,Yuanyuan Hou,Mingzhu Qi,Yongxiang Zhang,Chao Han,Hui Sun,Jiang Li

DOI: https://doi.org/10.2174/0118715303261924231117055702

2024-01-16

Abstract:Background:: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection attacks the respiratory and nervous systems. Among patients with SARS-CoV-2 infection, cases with simultaneous central and peripheral nervous system damage are rare, and those with intractable hypophosphatemia and hypokalemia complicating the former have not been reported yet. Case Presentation:: A 59-year-old woman presented to the emergency department with incoherent speech evolving for 3 days. She had tested positive for the SARS-CoV-2 RT-PCR assay 8 days earlier. Her physical examination showed progressive limb weakness with diminished tendon reflexes and normal sensory examination. Cranial MRI revealed multiple abnormal signals in the brain. Cerebrospinal fluid (CSF) analysis and electromyography revealed acute motor axonal neuropathy (AMAN), further diagnosed as encephalitis combined with Guillain‐Barré syndrome (GBS). The patient received glucocorticoid therapy, intravenous immune globulin (IVIG), and rehabilitation therapy. The patient experienced an intractable hypophosphatemia and hypokalemia during the treatment period, which was not effectively corrected several times. The symptoms improved after 1 month of treatment. Conclusion:: Early diagnosis is important for the management of Guillain-Barré syndrome associated with SARS-CoV-2 infection. Moreover, in order to prevent life-threatening long-term persistent electrolyte disturbances in non-seriously ill patients, clinicians should pay particular attention to their electrolyte status.

pharmacology & pharmacy,immunology,endocrinology & metabolism
[Incorporation of labelled substance by cells in vitro as a measure of the suitability of the culture medium].

H. Wrba,R. Kageyama,Rabesh,A. Geipel

Zeitschrift für Zellforschung und Mikroskopische Anatomie

Abstract:
Complex Neurological Sequelae: Axonal Guillain-Barré Syndrome Post COVID-19 in a Young Patient

Anam Umar,Amber E Faquih,Bilal Jawed,Muhammad Bilal

DOI: https://doi.org/10.7759/cureus.67213

2024-08-19

Cureus

Abstract:Guillain-Barré syndrome (GBS) encompasses a spectrum of immune-mediated neuropathies, with axonal GBS representing a less common yet often severe subtype. This variant directly damages peripheral nerve axons, resulting in rapid and profound muscle weakness and sensory deficits. Axonal GBS has similar clinical features to the demyelinating form but is generally more severe with a less favorable prognosis. Here, we present a case of axonal GBS in a 46-year-old female following a mild COVID-19 infection, highlighting the diagnostic challenges and the importance of tailored therapeutic approaches and multidisciplinary care in managing this condition.
COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too?

Farman Khan,Praveen Sharma,Saurabh Pandey,Deepak Sharma,Neeraj Kumar,Suruchi Shukla,Himanshu Dandu,Amita Jain,Vijayavarman V.,Ravindra K. Garg,Hardeep S. Malhotra

DOI: https://doi.org/10.1002/jmv.27159

IF: 20.693

2021-07-06

Journal of Medical Virology

Abstract:<p>COVID-19 has been shown to be associated with a lot of neurological complications, of whom Guillain Barre syndrome (GBS) is an important post-infectious consequentiality. More than 220 patients of GBS have been reported thus far. We intend to share our experience with 5 patients of GBS where one of them had SARS-Cov-2 in the cerebrospinal fluid (CSF). This is the first ever report demonstrating the presence of SARS-Cov-2 in the CSF of an adult patient; a similar occurrence has recently been described in a pediatric patient. We wish to emphasize the fact that commonly GBS occurs as a result of a post-infectious process but in few cases where the symptoms of COVID-19 and GBS occur concurrently, corresponding to viremic phase, a separate pathogenesis needs to be thought of. This para-infectious nature is exemplified by the presence of virus in the cerebrospinal fluid of one of our patients. We review the neuroinvasive potential of SARS-Cov-2 in this regard and draw parallels with Cytomegalovirus, Zika virus and Human Immunodeficiency virus-associated occurrences of GBS.</p><p>This article is protected by copyright. All rights reserved.</p>

virology
Guillain-Barré syndrome in ulcerative colitis and SARS-CoV-2 infection: a case report and literature review

Shema Ayadi,Rabeb Hammouga,Mohamed Slim Majoul,Hela Jamoussi,Yosra Zaimi,Asma Mensi,Mohamed Fredj,Leila Mouelhi

DOI: https://doi.org/10.2144/fsoa-2023-0125

2024-05-20

Abstract:Aim: Guillain-Barré syndrome (GBS) occurrence is rare during inflammatory bowel disease (IBD) and SARS-CoV-2 infection. Its association with thrombotic vascular events, which are common during these two entities, is extremely rare. Case report: We report an exceptional association of GBS and cerebral venous thrombosis in a 28-year-old woman with active ulcerative colitis and no previous history of SARS-CoV-2 vaccination. Mildly symptomatic SARS-CoV-2 infection was diagnosed during etiological investigations of cerebral venous thrombosis. GBS symptoms began 10 days later with clinical and electrical abnormalities consistent with axonal GBS. Other GBS causes were excluded. Favorable outcomes were noted after intravenous immunoglobulin perfusion with full recovery 12 months later. Conclusion: Greater attention should be focused on IBD patients with SARS-CoV-2 infection regardless of its severity.
Isotopes in general practice.

P. J. Hurley

Abstract:
Gonorrhea in the female.

M. Parker

Abstract:
The effect of calcium ions on the respiration of kidney slices of newborn and mature rats

M. Cutting,R. Mccance

DOI: https://doi.org/10.1113/jphysiol.1947.sp004220

1947-10-15

Journal of Physiology

Abstract:
Acute Lower-Extremity Ischemia in a Patient with COVID-19

Hadia Ahmad,Swhaeb M Shubair,James Kruer,Chehada Anthony Hatoum

DOI: https://doi.org/10.12659/AJCR.928471

2021-01-31

Abstract:BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has become a global pandemic. The typical symptoms are fever, cough, and shortness of breath, but the disease can present with atypical signs, including those associated with a hypercoagulable state. These signs include deep venous thrombosis, pulmonary embolism, ischemic stroke, and acute coronary syndrome. Herein, we present the case of acute bilateral lower-extremity ischemia as a thromboembolic complication in a patient with COVID-19. CASE REPORT A 76-year-old woman presented with acute bilateral lower-extremity ulcerations covered with eschar formation of several weeks' duration. During her hospital course, she underwent a test for COVID-19 and the result was positive. An angiogram of the patient's lower extremities showed occlusions of the right distal posterior tibial artery, right mid-distal anterior tibial artery, right dorsalis pedis artery, left mid-distal anterior tibial artery, left dorsalis pedis artery, and left popliteal vein. Tissue plasminogen activator was administered to treat the occlusions. On the following day, the patient had an acute decline in her neurologic state and was emergently intubated. A computed tomography scan of the brain confirmed a subarachnoid hemorrhage requiring reversal of tissue plasminogen activator. The patient was transitioned to comfort care and ultimately died. CONCLUSIONS In conclusion, acute limb ischemia should be acknowledged as a rare complication associated with COVID-19. It is important to raise awareness of arterial thrombosis as a possible complication of the hypercoagulable state caused by SARS-CoV-2 because prompt recognition is essential for early diagnosis and treatment. These actions could have a significant impact on patients' overall outcome.
Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection

Ricardo Rigual,Gerardo Ruiz-Ares,Jorge Rodriguez-Pardo,Andrés Fernández-Prieto,Pedro Navia,Joan R Novo,María Alonso de Leciñana,Pablo Alonso-Singer,Blanca Fuentes,Exuperio Díez-Tejedor

DOI: https://doi.org/10.1097/NRL.0000000000000403

2022-05-01

Abstract:Introduction: Thrombotic events are potentially devastating complications of coronavirus disease 2019 (COVID-19) infection. Although less common than venous thromboembolism, arterial thrombosis has been reported in COVID-19 cohorts in almost 3% of patients. We describe a patient with COVID-19 infection and concurrent cerebral and noncerebral infarction. Case report: A 53-year-old man with history of COVID-19 pneumonia was admitted to a primary stroke center for speech disturbances and left hemiplegia. Urgent laboratory tests showed a great increase of inflammatory and coagulation parameters as D-dimer, ferritin, interleukin-6 and C-reactive protein. Neuroimaging found occlusion of the M1 segment of the right middle cerebral artery with early signs of ischemic stroke. He received intravenous thrombolysis and mechanical thrombectomy. Abdominal computed tomography discovered a splenic infarction with hemorrhagic transformation and bilateral renal infarction. Urgent angiography showed an associated splenic pseudoaneurysm, which was embolized without complications. He was treated with intermediate-dose anticoagulation (1 mg subcutaneous enoxaparin/kg/24 h), acetylsalicylic acid 100 mg and 5 days of intravenous corticosteroids. In the following days, inflammatory markers decreased so anticoagulant treatment was stopped and acetylsalicylic acid 300 mg was prescribed. His condition improved and he was discharged to a rehabilitation facility on hospital day 30. Conclusion: In this case, a patient with multiple thrombotic events in the acute phase of COVID-19 infection, the delimitation of the inflammatory state through analytical markers as D-dimer helped to individualize the antithrombotic treatment (full anticoagulation or anticoagulation at intermediate doses plus antiplatelet treatment as used in our patient) and its duration. However, more data are needed to better understand the mechanisms and treatment of stroke in patients with COVID-19 infection.

Guest editorial: How do we apply genetic testing for breast cancer susceptibility to clinical practice?

A Case of Guillain-Barré Syndrome Associated With COVID-19

COVID-19 AND NEUROLOGICAL AUTOIMMUNITY: A CASE OF SARS-COV-2-INDUCED GUILLAIN-BARRÉ SYNDROME

CPR training. Finally, system sellers are laying out real-world steps to computerized patient records.

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication

Bilateral Facial Paralysis in an Atypical Clinical Onset of COVID-Associated Guillain-Barre Syndrome

Case report: Rare Guillain-Barré syndrome variants and mild encephalitis/encephalopathy with a reversible splenial lesion as the para-infectious manifestations of SARS-CoV-2 infection

HYGIENIC EVALUATION OF THE FOOD FISHES, TILAPIA MELANOPLEURA AND TILAPIA MOSSAMBICA NURTURED IN SEWAGE EFFLUENT.

Guillain-Barré Syndrome Complicated by Severe Acute Respiratory Distress Syndrome: A Case Report

Bradycardia unresponded to atropin testing was successfully treated with therapeutic plasma exchange in a patient with severe COVID-19 complicated by Guillain-Barré syndrome: A case report

A Case of Intractable Hypophosphatemia in a Patient with Guillain-Barré Syndrome and Encephalitis after SARS-CoV-2 Infection

[Incorporation of labelled substance by cells in vitro as a measure of the suitability of the culture medium].

Complex Neurological Sequelae: Axonal Guillain-Barré Syndrome Post COVID-19 in a Young Patient

COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too?

Guillain-Barré syndrome in ulcerative colitis and SARS-CoV-2 infection: a case report and literature review

Isotopes in general practice.

Gonorrhea in the female.

The effect of calcium ions on the respiration of kidney slices of newborn and mature rats

Acute Lower-Extremity Ischemia in a Patient with COVID-19

Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection